Total Payments
$619,706
2024 Payments
$35,437
Companies
28
Transactions
373
Medicare Patients
1,356
Medicare Billing
$350,692
Payment Breakdown by Category
Consulting$416,545 (67.2%)
Research$83,685 (13.5%)
Other$52,940 (8.5%)
Travel$43,597 (7.0%)
Education$15,864 (2.6%)
Food & Beverage$7,074 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $416,545 | 129 | 67.2% |
| Unspecified | $83,685 | 38 | 13.5% |
| Travel and Lodging | $43,597 | 67 | 7.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,265 | 8 | 3.9% |
| Honoraria | $21,575 | 11 | 3.5% |
| Education | $15,864 | 1 | 2.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,100 | 2 | 1.1% |
| Food and Beverage | $7,074 | 117 | 1.1% |
Payments by Type
General
$536,021
335 transactions
Research
$83,685
38 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $143,532 | 65 | $0 (2024) |
| Daiichi Sankyo Inc. | $69,061 | 32 | $0 (2024) |
| ABBVIE INC. | $64,328 | 38 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $64,196 | 51 | $0 (2023) |
| SERVIER PHARMACEUTICALS LLC | $47,408 | 31 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $37,399 | 40 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $33,850 | 6 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $25,747 | 5 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $24,621 | 19 | $0 (2023) |
| Genentech USA, Inc. | $21,288 | 24 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,437 | 31 | SERVIER PHARMACEUTICALS LLC ($9,358) |
| 2023 | $57,762 | 49 | SERVIER PHARMACEUTICALS LLC ($19,416) |
| 2022 | $107,740 | 62 | ABBVIE INC. ($49,655) |
| 2021 | $105,854 | 46 | Takeda Pharmaceuticals U.S.A., Inc. ($33,850) |
| 2020 | $66,029 | 27 | E.R. Squibb & Sons, L.L.C. ($15,864) |
| 2019 | $121,479 | 69 | Celgene Corporation ($51,027) |
| 2018 | $50,793 | 43 | Celgene Corporation ($20,992) |
| 2017 | $74,613 | 46 | Celgene Corporation ($49,631) |
All Payment Transactions
373 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 12/06/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $7.14 | General |
| Category: Genetically Defined Disease | ||||||
| 12/03/2024 | LES LABORATOIRES SERVIER | Tibsovo (Drug) | Consulting Fee | Cash or cash equivalent | $4,760.00 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Kyowa Kirin, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 08/21/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Travel and Lodging | In-kind items and services | $7.99 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 08/08/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Consulting Fee | Cash or cash equivalent | $3,870.00 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Consulting Fee | Cash or cash equivalent | $3,225.00 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Consulting Fee | Cash or cash equivalent | $2,720.00 | General |
| Category: Oncology | ||||||
| 07/11/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $71.28 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $58.99 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $57.01 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $46.08 | General |
| 06/15/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $42.64 | General |
| Category: BioOncology | ||||||
| 04/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,558.00 | General |
| 04/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: Oncology | ||||||
| 04/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $489.20 | General |
| Category: Oncology | ||||||
| 04/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $275.59 | General |
| Category: Oncology | ||||||
| 04/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $46.15 | General |
| Category: Oncology | ||||||
| 04/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $21.85 | General |
| Category: Oncology | ||||||
| 04/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $17.34 | General |
| Category: Oncology | ||||||
| 04/11/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $348.19 | General |
| Category: Oncology | ||||||
| 04/05/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $27.72 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA | Takeda Pharmaceuticals U.S.A., Inc. | $33,850 | 6 |
| AG-221-C-001 | Celgene Corporation | $10,059 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $8,368 | 6 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,656 | 11 |
| A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation (AG-221-C-001) | Celgene Corporation | $6,106 | 1 |
| AG-221-C-001 - A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hemat | Celgene Corporation | $5,857 | 1 |
| STUDY OF AG-120 (IVOSIDENIB) VS. PLACEBO IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA WITH AN IDH1 MUTATION (AGILE) | SERVIER AFFAIRES MEDICALES | $2,867 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,422 | 3 |
| AG-221-AML-005 - Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) | Celgene Corporation | $1,966 | 1 |
| ((OBU) Sabatolimab )_MBG-AB -114225_RWE | Novartis Pharmaceuticals Corporation | $1,744 | 1 |
| Safety, efficacy, and pharmacokinetics/pharmacodynamics of vorasidenib in patients with mIDH1/2 acute myeloid leukemia: a phase 1 study | Servier BioInnovation | $1,683 | 4 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $1,106 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 342 | 870 | $504,325 | $81,216 |
| 2022 | 5 | 329 | 895 | $527,050 | $87,160 |
| 2021 | 7 | 404 | 1,218 | $696,775 | $119,179 |
| 2020 | 8 | 281 | 770 | $397,695 | $63,137 |
Total Patients
1,356
Total Services
3,753
Medicare Billing
$350,692
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 548 | $298,660 | $45,944 | 15.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 79 | $57,670 | $9,959 | 17.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 92 | $47,840 | $9,827 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 59 | 59 | $61,655 | $9,437 | 15.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 76 | $28,500 | $4,397 | 15.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 16 | 16 | $10,000 | $1,653 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 142 | 553 | $301,385 | $49,033 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 55 | 103 | $76,220 | $13,585 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 66 | 66 | $68,970 | $10,916 | 15.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 104 | $54,600 | $9,670 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 69 | $25,875 | $3,956 | 15.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 140 | 666 | $362,970 | $60,048 | 16.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 41 | 247 | $124,735 | $23,564 | 18.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 57 | 101 | $72,720 | $13,294 | 18.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 77 | 77 | $80,465 | $12,665 | 15.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 55 | 92 | $34,500 | $5,608 | 16.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 14 | $13,930 | $2,594 | 18.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 21 | 21 | $7,455 | $1,407 | 18.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 77 | 296 | $153,920 | $21,595 | 14.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 40 | 216 | $106,920 | $20,718 | 19.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 49 | $33,810 | $5,088 | 15.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 28 | 28 | $28,290 | $4,434 | 15.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 43 | 90 | $31,950 | $4,215 | 13.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 23 | 36 | $18,720 | $2,249 | 12.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 12 | $11,640 | $2,241 | 19.3% |
About Dr. Eytan Stein, M.D
Dr. Eytan Stein, M.D is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1114100047.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eytan Stein, M.D has received a total of $619,706 in payments from pharmaceutical and medical device companies, with $35,437 received in 2024. These payments were reported across 373 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($416,545).
As a Medicare-enrolled provider, Stein has provided services to 1,356 Medicare beneficiaries, totaling 3,753 services with total Medicare billing of $350,692. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location New York, NY
- Active Since 12/13/2007
- Last Updated 04/07/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1114100047
Products in Payments
- VENCLEXTA (Drug) $56,228
- Tibsovo (Drug) $46,602
- TIBSOVO (Drug) $43,515
- RYDAPT (Drug) $42,333
- Idhifa (Drug) $35,107
- VYXEOS (Drug) $24,621
- Vidaza (Drug) $20,041
- OPDIVO (Biological) $15,864
- VENCLEXTA (Biological) $15,563
- MBG453 (Biological) $8,695
- Vanflyta (Drug) $7,290
- IDHIFA (Drug) $5,501
- IMBRUVICA (Drug) $5,480
- REBLOZYL (Biological) $4,884
- Venclexta (Biological) $3,416
- TAZVERIK (Drug) $3,400
- AYVAKIT (Drug) $2,340
- PYRUKYND (Drug) $2,269
- ONUREG (Drug) $2,009
- Non-Covered Product (Drug) $1,650
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M